Monopar Therapeutics Inc. held its Annual Meeting on June 17, 2025. During the meeting, stockholders voted on several proposals. The election of six directors to the Board of Directors was approved. The compensation of the Company's named executive officers was approved on an advisory, non-binding basis. Additionally, stockholders approved holding future advisory votes on executive compensation every year. The selection of BPM LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025, was also ratified.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.